Eptinezumab

Eptinezumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	CALCA, CALCB
Clinical data
Trade names	Vyepti
Other names	ALD403, eptinezumab-jjmr
AHFS/Drugs.com	Monograph
MedlinePlus	a620022
License data	US DailyMed: Eptinezumab;
Pregnancy; category	AU: B1;
Routes of; administration	Intravenous
Drug class	Calcitonin gene-related peptide antagonist
ATC code	N02CD05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1644539-04-7;
DrugBank	DB14040;
ChemSpider	none;
UNII	8202AY8I7H;
KEGG	D11303;
Chemical and physical data
Formula	C6352H9838N1694O1992S46
Molar mass	143283.20 g·mol−1

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.

Eptinezumab was approved for medical use in the United States in February 2020, and in the European Union in January 2022.